Recent submissions

  • Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP. 

    Huddart, RA; Reid, AM
    Testicular germ cell tumours are the commonest tumours of young men and are broadly managed either as pure seminomas or as 'nonseminomas'. The management of Stage 1 nonseminomatous germ cell tumours (NSGCTs), beyond surgical ...
  • Ripk1 and haematopoiesis: a case for LUBAC and Ripk3. 

    Annibaldi, A; Meier, P (2018-06-04)
  • In Vivo Validation of Elekta's Clarity Autoscan for Ultrasound-based Intrafraction Motion Estimation of the Prostate During Radiation Therapy. 

    Grimwood, A; McNair, HA; O'Shea, TP; Gilroy, S; Thomas, K; Bamber, JC; Tree, AC; Harris, EJ (2018-04-16)
    PURPOSE: Our purpose was to perform an in vivo validation of ultrasound imaging for intrafraction motion estimation using the Elekta Clarity Autoscan system during prostate radiation therapy. The study was conducted as ...
  • A Dosimetric Comparison of Breast Radiotherapy Techniques to Treat Locoregional Lymph Nodes Including the Internal Mammary Chain. 

    Ranger, A; Dunlop, A; Hutchinson, K; Convery, H; Maclennan, MK; Chantler, H; Twyman, N; Rose, C; McQuaid, D; Amos, RA; Griffin, C; deSouza, NM; Donovan, E; Harris, E; Coles, CE; Kirby, A
    AIMS: Radiotherapy target volumes in early breast cancer treatment increasingly include the internal mammary chain (IMC). In order to maximise survival benefits of IMC radiotherapy, doses to the heart and lung should be ...
  • Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants 

    Dadaev, T; Saunders, EJ; Newcombe, PJ; Anokian, E; Leongamornlert, DA; Brook, MN; Cieza-Borrella, C; Mijuskovic, M; Wakerell, S; Olama, AAA; Schumacher, FR; Berndt, SI; Benlloch, S; Ahmed, M; Goh, C; Sheng, X; Zhang, Z; Muir, K; Govindasami, K; Lophatananon, A; Stevens, VL; Gapstur, SM; Carter, BD; Tangen, CM; Goodman, P; Thompson, IM; Batra, J; Chambers, S; Moya, L; Clements, J; Horvath, L; Tilley, W; Risbridger, G; Gronberg, H; Aly, M; Nordström, T; Pharoah, P; Pashayan, N; Schleutker, J; Tammela, TLJ; Sipeky, C; Auvinen, A; Albanes, D; Weinstein, S; Wolk, A; Hakansson, N; West, C; Dunning, AM; Burnet, N; Mucci, L; Giovannucci, E; Andriole, G; Cussenot, O; Cancel-Tassin, G; Koutros, S; Freeman, LEB; Sorensen, KD; Orntoft, TF; Borre, M; Maehle, L; Grindedal, EM; Neal, DE; Donovan, JL; Hamdy, FC; Martin, RM; Travis, RC; Key, TJ; Hamilton, RJ; Fleshner, NE; Finelli, A; Ingles, SA; Stern, MC; Rosenstein, B; Kerns, S; Ostrer, H; Lu, Y-J; Zhang, H-W; Feng, N; Mao, X; Guo, X; Wang, G; Sun, Z; Giles, GG; Southey, MC; MacInnis, RJ; FitzGerald, LM; Kibel, AS; Drake, BF; Vega, A; Gómez-Caamaño, A; Fachal, L; Szulkin, R; Eklund, M; Kogevinas, M; Llorca, J; Castaño-Vinyals, G; Penney, KL; Stampfer, M; Park, JY; Sellers, TA; Lin, H-Y; Stanford, JL; Cybulski, C; Wokolorczyk, D; Lubinski, J; Ostrander, EA; Geybels, MS; Nordestgaard, BG; Nielsen, SF; Weisher, M; Bisbjerg, R; Røder, MA; Iversen, P; Brenner, H; Cuk, K; Holleczek, B; Maier, C; Luedeke, M; Schnoeller, T; Kim, J; Logothetis, CJ; John, EM; Teixeira, MR; Paulo, P; Cardoso, M; Neuhausen, SL; Steele, L; Ding, YC; De Ruyck, K; De Meerleer, G; Ost, P; Razack, A; Lim, J; Teo, S-H; Lin, DW; Newcomb, LF; Lessel, D; Gamulin, M; Kulis, T; Kaneva, R; Usmani, N; Slavov, C; Mitev, V; Parliament, M; Singhal, S; Claessens, F; Joniau, S; Van den Broeck, T; Larkin, S; Townsend, PA; Aukim-Hastie, C; Gago-Dominguez, M; Castelao, JE; Martinez, ME; Roobol, MJ; Jenster, G; van Schaik, RHN; Menegaux, F; Truong, T; Koudou, YA; Xu, J; Khaw, K-T; Cannon-Albright, L; Pandha, H; Michael, A; Kierzek, A; Thibodeau, SN; McDonnell, SK; Schaid, DJ; Lindstrom, S; Turman, C; Ma, J; Hunter, DJ; Riboli, E; Siddiq, A; Canzian, F; Kolonel, LN; Le Marchand, L; Hoover, RN; Machiela, MJ; Kraft, P; Freedman, M; Wiklund, F; Chanock, S; Henderson, BE; Easton, DF; Haiman, CA; Eeles, RA; Conti, DV; Kote-Jarai, Z
  • CNS cancer immunity cycle and strategies to target this for glioblastoma. 

    Ameratunga, M; Coleman, N; Welsh, L; Saran, F; Lopez, J (2018-04-27)
    Immunotherapeutics have revolutionized the management of solid malignancies over the last few years. Nevertheless, despite relative successes of checkpoint inhibitors in numerous solid tumour types, success in tumours of ...
  • The psychosocial impact of undergoing prostate cancer screening for men with BRCA1/2 mutations. 

    Bancroft, EK; Saya, S; Page, EC; Myhill, K; Thomas, S; Pope, J; Chamberlain, A; Hart, R; Glover, W; Cook, J; Rosario, DJ; Helfand, BT; Selkirk, CH; Davidson, R; Longmuir, M; Eccles, DM; Gadea, N; Brewer, C; Barwell, J; Salinas, M; Greenhalgh, L; Tischkowitz, M; Henderson, A; Evans, DG; Buys, SS; IMPACT Study Steering Committee; IMPACT Collaborators; Eeles, RA; Aaronson, NK (2018-05-26)
    OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic ...
  • Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. 

    Wilkerson, PM; Dedes, KJ; Samartzis, EP; Dedes, I; Lambros, MB; Natrajan, R; Gauthier, A; Piscuoglio, S; Töpfer, C; Vukovic, V; Daley, F; Weigelt, B; Reis-Filho, JS (2017-01-24)
    PURPOSE: To determine if models of ovarian clear cell carcinomas (OCCCs) harbouring defects in homologous recombination (HR) DNA repair of double strand breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition. ...
  • Variation of mutational burden in healthy human tissues suggests non-random strand segregation and allows measuring somatic mutation rates. 

    Werner, B; Sottoriva, A (2018-06-07)
    The immortal strand hypothesis poses that stem cells could produce differentiated progeny while conserving the original template strand, thus avoiding accumulating somatic mutations. However, quantitating the extent of ...
  • Splicing dysregulation as a driver of breast cancer 

    Read, A; Natrajan, R (2018-05-30)
  • Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. 

    Natrajan, R; Tutt, ANJ; Lord, CJ
    Two reports in this issue of Cancer Discovery outline how the genomic composition of tumors, including the presence of intragenic gene fusions, could inform the selection of treatment approaches in aggressive forms of the ...
  • Noninvasive detection of HER2 amplification with plasma DNA digital PCR. 

    Gevensleben, H; Garcia-Murillas, I; Graeser, MK; Schiavon, G; Osin, P; Parton, M; Smith, IE; Ashworth, A; Turner, NC (2013-06)
    PURPOSE: Digital PCR is a highly accurate method of determining DNA concentration. We adapted digital PCR to determine the presence of oncogenic amplification through noninvasive analysis of circulating free plasma DNA and ...
  • A paradox: urgent BRCA genetic testing. 

    Mitchell, G; Ardern-Jones, A; Kissin Mchir, M; Taylor, R; Eeles, RA (2001-01)
    Diagnostic or predictive testing for germline mutations in cancer predisposition genes is inherently slow as result of both genetic counselling and mutation analysis. The overall time taken for mutation testing is not ...
  • Genetic mechanisms in squamous cell carcinoma of the head and neck. 

    Jefferies, s
    Genetic mechanisms in squamous cell carcinoma of the head and neck. This review aims to explore the genetic mechanisms involved in the development of squamous cell carcinoma of the head and neck (SCCHN). The epidemiology ...
  • Mortality and cancer incidence in persons with Down's syndrome, their parents and siblings. 

    Hermon, C; Alberman, E; Beral, V; Swerdlow, AJ (2001-03)
    A cohort study of 1425 persons with Down's syndrome (DS), and of their parents (447 mothers, 435 fathers) and siblings (1176), was set up to investigate death rates from various causes and cancer incidence patterns. In ...
  • Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: a cohort study. 

    Swerdlow, AJ; Hermon, C; Jacobs, PA; Alberman, E; Beral, V; Daker, M; Fordyce, A; Youings, S (2001-03)
    Mortality and cancer incidence were assessed in a cohort of 1373 patients with numerical sex chromosome abnormalities diagnosed at three cytogenetics centres in Britain during 1959-90, and were compared with expectations ...
  • The Silver syndrome variant of hereditary spastic paraplegia maps to chromosome 11q12-q14, with evidence for genetic heterogeneity within this subtype. 

    Patel, H; Hart, PE; Warner, TT; Houlston, RS; Patton, MA; Jeffery, S; Crosby, AH (2001-07)
    The hereditary spastic paraplegias (HSPs) are a complex group of neurodegenerative disorders characterized by lower-limb spasticity and weakness. Silver syndrome (SS) is a particularly disabling dominantly inherited form ...
  • Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease. 

    Popat, S; Hearle, N; Hogberg, L; Braegger, CP; O'Donoghue, D; Falth-Magnusson, K; Holmes, GK; Howdle, PD; Jenkins, H; Johnston, S; Kennedy, NP; Kumar, PJ; Logan, RF; Marsh, MN; Mulder, CJ; Torinsson Naluai, A; Sjoberg, K; Stenhammar, L; Walters, JR; Jewell, DP; Houlston, RS (2002-03)
    Susceptibility to coeliac disease involves HLA and non-HLA-linked genes. The CTLA4/CD28 gene region encodes immune regulatory T-cell surface molecules and is a strong candidate as a susceptibility locus. We evaluated ...

View more